Organ‐Specific Human Microbiomes and Dysbiosis: Mechanistic Links to Disease and Emerging Therapeutic Strategies
Author:
Open Access
- 6 July 2026
- journal article
- review article
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 40 (18) , e70307
Abstract
Background: The human microbiome is a dynamic and diverse community of microorganisms that affects susceptibility to illness and promotes wellness. Dysbiosis, or disruption of this delicately regulated microbial ecology, has been identified as a major factor in the emergence and development of systemic and organ‐specific disorders. Objective: With an emphasis on dysbiosis‐driven illness processes and therapeutic intervention implications, this study attempts to critically analyze host–microbiome interactions across key human organ systems. Methods: Using predetermined microbiome‐related keywords, a systematic literature search (2001–2025) was carried out in PubMed, Scopus, Web of Science, and Google Scholar. To assess microbiome formation, organ‐specific distribution, disease correlations, and therapeutic implications, English‐language peer‐reviewed original papers, meta‐analyses, and clinical or validated animal studies were chosen and methodically compiled. Results: Microbiome dysbiosis is linked to cardiovascular, metabolic, inflammatory, neurological, hepatic, renal, and cancer‐related illnesses by interfering with immune modulation, metabolic balance, and epithelial barrier integrity, according to evidence from human and verified animal research. Modified production of short‐chain fatty acids, immunological signaling imbalance, chronic inflammation, and communication between the gut–organ axis are examples of mechanistic linkages. Immune and metabolic indicators improved condition‐specifically with interventions such as probiotics, fecal microbiota transplantation, and diet‐based regulation. Conclusion: Collectively, current evidence supports the microbiome as a modifiable determinant of disease risk and therapeutic response, underscoring its translational potential for precision medicine.Keywords
This publication has 218 references indexed in Scilit:
- Navigating PROTACs in Cancer Therapy: Advancements, Challenges, and Future HorizonsFood Science & Nutrition, 2025
- Advancing brain tumor therapy: unveiling the potential of PROTACs for targeted protein degradationCytotechnology, 2025
- The clinical praxis of bacteriocins as natural anti-microbial therapeuticsArchives of Microbiology, 2024
- Building a Better Microbiome: Advances in Microbiome Engineering for Human Health2024
- The role of inflammation and the gut microbiome in depression and anxietyJournal of Neuroscience Research, 2019
- The role of microbiota in the development of colorectal cancerInternational Journal of Cancer, 2018
- Oral microbiome activity in children with autism spectrum disorderAutism Research, 2018
- Altered gut microbiota and microbial biomarkers associated with chronic kidney diseaseMicrobiologyopen, 2018
- Mortality in Mental Disorders and Global Disease Burden ImplicationsJAMA Psychiatry, 2015
- Intestinal microbiota in patients with nonalcoholic fatty liver diseaseHepatology, 2013